Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 5:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 3,096 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: MCG Clear all
Completed Phase 2 Interventional Results available

Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma

NCT00066365
View directory record Official record
Conditions
Metastatic Cancer, Sarcoma
Interventions
sargramostim, conventional surgery
Biological · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 39 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
83
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Oct 26, 2026, 5:44 PM EDT
Completed Not applicable Interventional

Coronary Artery Disease in Patients With Friedreich's Ataxia

NCT04649866
View directory record Official record
Conditions
Friedreich Ataxia
Interventions
plethysmography
Diagnostic Test
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 79 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 26, 2026, 5:44 PM EDT
Completed Phase 2Phase 3 Interventional

To Study the Efficacy and Safety of Doxercalciferol on Spinal and Femoral Density in Postmenopausal Osteopenic Women in a Long Term 2 Year Study

NCT07660536
View directory record Official record
Conditions
Osteoporosis (Senile)
Interventions
doxercalciferol capsules, Hectorol®, Matched Placebo (Capsules)
Drug
Lead sponsor
Creighton University
Other
Eligibility
60 Years to 78 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1989 – 1994
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 26, 2026, 5:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Clinical Evaluation of PROPEL® Contour Sinus Implant

NCT04858802
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis)
Interventions
PROPEL Contour Sinus Implant, Balloon Sinus Dilation Alone
Device · Procedure
Lead sponsor
Intersect ENT
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
14
States / cities
Sacramento, California • San Francisco, California • Boca Raton, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 26, 2026, 5:44 PM EDT
Completed Phase 3 Interventional Results available

MGR001 / Advair Diskus Local Equivalence Study in Asthma

NCT02245672
View directory record Official record
Conditions
Asthma
Interventions
MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate), Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate), Placebo
Drug
Lead sponsor
Mylan Pharma UK Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1,128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
101
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 84 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 26, 2026, 5:44 PM EDT
Completed Early Phase 1 Interventional

Dexmedetomidine Pharmacokinetics in Neonates During Therapeutic Hypothermia

NCT02529202
View directory record Official record
Conditions
Hypoxic-ischemic Encephalopathy
Interventions
Dexmedetomidine
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Hour to 1 Day
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 26, 2026, 5:44 PM EDT
Not listed Phase 3 Interventional

Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH

NCT02652429
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Inhaled Nitric Oxide
Drug
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 26, 2026, 5:44 PM EDT
Completed Phase 3 Interventional

A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT00047645
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Interferon-gamma 1b
Drug
Lead sponsor
InterMune
Industry
Eligibility
20 Years to 79 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 2, 2007 · Synced Oct 26, 2026, 5:44 PM EDT
Terminated Phase 1 Interventional

Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma

NCT00977145
View directory record Official record
Conditions
Melanoma
Interventions
A combination of intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1
Biological
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 26, 2026, 5:44 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIV

NCT05903339
View directory record Official record
Conditions
Hiv
Interventions
V3G CH848 Pr-NP1 60mcg, 3M-052-AF 5mcg, Alum 500 mcg, V3G CH848 mRNA-Tr2 50mcg, ACU-026-001-1 2.0mg, V3G CH848 Pr-NP1 100mcg
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
6
States / cities
Birmingham, Alabama • Atlanta, Georgia • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 26, 2026, 5:44 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Medication Abortion Via Pharmacy Dispensing

NCT03320057
View directory record Official record
Conditions
Pregnancy Related, Abortion Early
Interventions
Mifepristone, Training on mifepristone dispensing
Drug · Other
Lead sponsor
Daniel Grossman
Other
Eligibility
15 Years and older · Female only
Enrollment
326 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
6
States / cities
Sacramento, California • San Diego, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 26, 2026, 5:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Interaction Between Calcium and Vitamin D Intake

NCT00762775
View directory record Official record
Conditions
Osteoporosis
Interventions
Calcium and vitamin D supplementation
Dietary Supplement
Lead sponsor
Winthrop University Hospital
Other
Eligibility
45 Years to 85 Years · Female only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Oct 26, 2026, 5:44 PM EDT
Completed Phase 3 Interventional

TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis

NCT00172081
View directory record Official record
Conditions
Osteoporosis
Interventions
placebo, ALX1-11
Drug
Lead sponsor
Shire
Industry
Eligibility
45 Years and older · Female only
Enrollment
2,532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
107
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 95 more
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 26, 2026, 5:44 PM EDT
Completed Phase 3 Interventional

Safety Study in Adolescent and Adult Patients With Asthma

NCT01476904
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Primatene Mist, Epinephrine inhalation
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
27
States / cities
Costa Mesa, California • Los Angeles, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2017 · Synced Oct 26, 2026, 5:44 PM EDT
Completed Not applicable Interventional Results available

Do Corticosteroid Injections During Total Knee Replacement Improve Early Clinical Results?

NCT00492973
View directory record Official record
Conditions
Osteoarthritis, Post-traumatic; Arthrosis
Interventions
methylprednisolone acetate, active comparator
Drug
Lead sponsor
New Lexington Clinic
Other
Eligibility
18 Years to 95 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 26, 2026, 5:44 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok

NCT00539981
View directory record Official record
Conditions
Influenza
Interventions
FluBlok®, Placebo
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 49 Years
Enrollment
4,648 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
24
States / cities
Beverly Hills, California • Sacramento, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Oct 26, 2026, 5:44 PM EDT
Not listed Phase 4 Interventional

Low Dose Vasopressin vs Phenylephrine in Cardiac Surgery

NCT04602767
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Vasopressin, Phenylephrine
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 26, 2026, 5:44 PM EDT
Terminated Phase 4 Interventional Results available

Postpartum Depression: Transdermal Estradiol Versus Sertraline

NCT00744328
View directory record Official record
Conditions
Postpartum Depression
Interventions
Transdermal Estradiol, Sertraline, Placebo
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 26, 2026, 5:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response of an H7N7 Vaccine in Healthy Adults

NCT01534468
View directory record Official record
Conditions
Influenza A Subtype H7N7 Infection
Interventions
Monovalent Influenza Subvirion Vaccine, H7N7
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Oct 26, 2026, 5:44 PM EDT
Terminated Phase 2 Interventional Results available

Teriparatide for Postsurgical Hypoparathyroidism

NCT01171690
View directory record Official record
Conditions
Hypoparathyroidism Post-surgical
Interventions
Teriparatide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced Oct 26, 2026, 5:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Chromium, Phyllanthus Emblica, and Shilajit on Cardiovascular Health, Fitness, and Weight Loss During Exercise and Diet Programs

NCT06641596
View directory record Official record
Conditions
Overweight, Metabolic Syndrome X
Interventions
Placebo, Cr-400, Cr-800, PE-500, PE-1000
Dietary Supplement
Lead sponsor
Kerry Group P.L.C
Industry
Eligibility
30 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 26, 2026, 5:44 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT04240002
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
Interventions
gilteritinib, fludarabine, cytarabine, granulocyte colony-stimulating factor (G-CSF)
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
6 Months to 21 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 26, 2026, 5:44 PM EDT
Completed Phase 3 Interventional

Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg With Nasonex Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

NCT02125253
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Mometasone Furoate Nasal Spray, 50 mcg, Nasonex Nasal Spray, 50 mcg, Placebo Nasal Spray
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older
Enrollment
811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
10
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Oct 26, 2026, 5:44 PM EDT
Completed Phase 2 Interventional Results available

A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD

NCT02038829
View directory record Official record
Conditions
COPD
Interventions
Placebo, SUN101 3 mcg, SUN-101 6.25 mcg, SUN-101 12.5 mcg, SUN-101 50 mcg, Aclidinium
Drug
Lead sponsor
Sunovion Respiratory Development Inc.
Industry
Eligibility
40 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
10
States / cities
Clearwater, Florida • Charlotte, North Carolina • Raleigh, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Oct 26, 2026, 5:44 PM EDT